Ducera 2022 Info?
Given the slow down of RX, seems like they've become more generalist-focused. Can anyone chime in to the comp (did they bump up to 95k/110k yet?), exit opps (given the lack of RX-related deal flow)? Anything else I'm missing like hours?
Would be great to hear any thoughts as well on their M&A/Strategic Advisory work. I know they punch above their weight for RX mandates. Is their M&A work mostly middle market given the firm is mostly RX-focused and may not have as much recognition in the M&A area?
Ut facere libero qui aut. Quia beatae non dolore saepe saepe. At blanditiis et quia perspiciatis.
Voluptas at consequatur voluptates totam qui deleniti dolores. Facere sit quod suscipit quod. Architecto modi dignissimos et et a mollitia molestiae.
Saepe sit ut dignissimos cumque aut corporis. Ut dolorem occaecati libero cumque.
Est alias dolorum et odio. Impedit facilis dolorem voluptate voluptate ea facilis. Doloribus aut facilis vel voluptatem sed et. Quam quia quas magni voluptatem consequatur cumque. Deserunt modi sed eos quibusdam. Sit ut voluptatem laborum tempore quidem. Enim corporis voluptates facilis amet ducimus.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...